Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exscientia Ltd.
Bristol Myers Squibb will in-license an immune-modulating drug candidate created by AI-pioneer Exscientia, the first in their expanded multi-target alliance announced in May.
EQRx has raised at least $750m since it launched in January 2020 and will have $2bn to fund its ongoing development of low-cost drugs after merging with a special purpose acquisition corporation.
Artificial Intelligence has been hyped as a game changer in drug discovery for the last five years. How far has it come, and how far can it go? In Vivo talks to some of the key players that are creating and shaping the future of the industry.
Deal Snapshot: Following its diabetes deal with Biolojic by four months, Lilly’s partnership with Verge on using AI to discover ALS drugs is just the latest of numerous tech-biopharma tie-ups.
- Digital Health
- Drug Discovery Tools
- Other Names / Subsidiaries
- Allcyte GmbH